Pharma BD Deal Intelligence
Danaher agreed to acquire antibody and reagent firm Abcam for $5.7 billion, with Abcam to operate as a standalone operating company within Danaher's Life…
Danaher has finalized its takeover of Abcam, a UK-based life sciences firm specializing in antibodies and consumables, for $5.7 billion in cash despite…
Post-close analyst review: Abcam integration into Danaher's Life Sciences segment ongoing; DHR trading ~11% below consensus target and ~13.8% below estimated…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Danaher acquired Abcam for $5.7B for antibodies, reagents, and proteomic research tools.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Danaher Corporation / Abcam PLC (this deal) | 2023 | $5.7B | 77 |
| Danaher Corporation / Pall Corporation | 2015 | $13.6B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |
| Summit Therapeutics plc / Akeso Inc. | 2023 | $4.5B | 79 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2023 deals · Danaher Corporation deals